Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth H Phillips

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
British Journal of Haematology|March 14, 2021
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Nicholas Counsell, Ruth de Tute, et al.
The Lancet. Haematology|December 18, 2022
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trialKwee Yong, William Wilson, Ruth M de Tute, et al.
British Journal of Haematology|October 12, 2021
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trialWei Yee Chan, Nicholas Counsell, Ruth de Tute, et al.
Blood|January 29, 2021
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic targetEmma Kennedy, Eve Coulter, Emma Halliwell, et al.
Blood Advances|January 12, 2022
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Wilson, Wendy Osborne, et al.
British Journal of Haematology|April 29, 2022
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experienceAndrea Kuhnl, Claire Roddie, Amy A Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
The Lancet. Oncology|December 14, 2024
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational studyAnna Santarsieri, Emily Mitchell, My H Pham, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
British Journal of Haematology|March 14, 2021
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Nicholas Counsell, Ruth de Tute, et al.
The Lancet. Haematology|December 18, 2022
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trialKwee Yong, William Wilson, Ruth M de Tute, et al.
British Journal of Haematology|October 12, 2021
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trialWei Yee Chan, Nicholas Counsell, Ruth de Tute, et al.
Blood|January 29, 2021
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic targetEmma Kennedy, Eve Coulter, Emma Halliwell, et al.
Blood Advances|January 12, 2022
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Wilson, Wendy Osborne, et al.
British Journal of Haematology|April 29, 2022
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experienceAndrea Kuhnl, Claire Roddie, Amy A Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
The Lancet. Oncology|December 14, 2024
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational studyAnna Santarsieri, Emily Mitchell, My H Pham, et al.
Pageof 3